FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

DM Johnson

Research Profile

Procedures

Microbial Sensitivity Tests

Living Beings

Chemicals & Drugs

Physiology

Microbial Drug Resistance

Co-author Network

Publications

TOP 3
Ronald Jones; Douglas J Biedenbach; DM Johnson
Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.
DM Johnson; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller; Ronald Jones
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Douglas J Biedenbach; DM Johnson; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of DM Johnson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2000: Ronald Jones; Douglas J Biedenbach; DM Johnson
Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.
Diagnostic microbiology and infectious disease 2000;37(2):143-6.
2000: DM Johnson; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller; Ronald Jones
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Diagnostic microbiology and infectious disease 2000;37(2):99-105.
1999: Douglas J Biedenbach; DM Johnson; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):325-31.
1999: Douglas J Biedenbach; DM Johnson; Ronald Jones
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):299-305.
1999: DM Johnson; Douglas J Biedenbach; Ronald Jones
In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):291-7.
1999: Ronald Jones; ME Erwin; Douglas J Biedenbach; DM Johnson; Michael A Pfaller
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Diagnostic microbiology and infectious disease 1999;35(3):227-34.
1999: Ronald Jones; DM Johnson; ME Erwin; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):91-8.
1999: DM Johnson; Ronald Jones; ME Erwin
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
Diagnostic microbiology and infectious disease 1999;33(2):87-91.
1998: Ronald Jones; DM Johnson
Combinations of orally administered beta-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1998;31(2):373-6.
1998: Ronald Jones; CH Ballow; Jerome J Schentag; DM Johnson; JA Deinhart
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Diagnostic microbiology and infectious disease 1998;31(1):313-25.
1997: CH Ballow; Ronald Jones; DM Johnson; JA Deinhart; Jerome J Schentag
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Diagnostic microbiology and infectious disease 1997;29(3):173-86.
1997: Shan Putnam; Ronald Jones; DM Johnson
In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1997;28(3):139-47.
1996: C M Flynn; DM Johnson; Ronald Jones
In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Journal of chemotherapy (Florence, Italy) 1996;8(6):411-5.
1996: DM Johnson; G V Doern; T A Haugen; J Hindler; JA Washington; Ronald Jones
Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests.
Diagnostic microbiology and infectious disease 1996;25(3):137-41.
1996: Ronald Jones; DM Johnson; ME Erwin
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrobial agents and chemotherapy 1996;40(3):720-6.
1996: DM Johnson; Ronald Jones
Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
Diagnostic microbiology and infectious disease 1996;24(1):53-7.
1995: Ronald Jones; DM Johnson; Douglas J Biedenbach; SA Marshall
Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
Diagnostic microbiology and infectious disease 1995;23(3):123-7.
1995: Ronald Jones; DM Johnson
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Diagnostic microbiology and infectious disease 1995;21(4):209-13.
1994: Ronald Jones; DM Johnson; ME Erwin
Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
Diagnostic microbiology and infectious disease 1994;18(2):125-7.
1993: DM Johnson; Ronald Jones; ME Erwin
In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones.
Diagnostic microbiology and infectious disease 1993;17(1):79-83.
1992: B B Gooding; ME Erwin; MS Barrett; DM Johnson; Ronald Jones
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.
Antimicrobial agents and chemotherapy 1992;36(9):2049-50.
1992: DM Johnson; ME Erwin; MS Barrett; B B Gooding; Ronald Jones
Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(8):751-5.
1992: DM Johnson; Ronald Jones
Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(2):181-8.
1991: Ronald Jones; ME Erwin; MS Barrett; B M Briggs; DM Johnson
In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester.
Diagnostic microbiology and infectious disease 1991;14(6):473-83.
1991: Ronald Jones; DM Johnson; MS Barrett; ME Erwin
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.
Journal of chemotherapy (Florence, Italy) 1991;3(5):289-94.
1991: B M Briggs; Ronald Jones; ME Erwin; MS Barrett; DM Johnson
In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Diagnostic microbiology and infectious disease 1991;14(5):425-34.
1991: MS Barrett; Ronald Jones; ME Erwin; DM Johnson; B M Briggs
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
Diagnostic microbiology and infectious disease 1991;14(5):389-401.
1991: Ronald Jones; MS Barrett; ME Erwin; B M Briggs; DM Johnson
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Diagnostic microbiology and infectious disease 1991;14(4):319-30.
1991: Ronald Jones; ME Erwin; MS Barrett; DM Johnson; B M Briggs
Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Diagnostic microbiology and infectious disease 1991;14(4):301-9.
1991: ME Erwin; Ronald Jones; MS Barrett; B M Briggs; DM Johnson
In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.
Antimicrobial agents and chemotherapy 1991;35(5):929-37.